ALK and non-small cell lung carcinoma: In a phase I/II clinical trial, crizotinib combined with nivolumab was used as a first-line treatment for advanced NSCLC patients with ALK-positive mutation, while multiple cases of severe hepatotoxic adverse reactions were reported.